The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Accelerate Diagnostics Inc | COM | 00430H102 | 1,077 | 74,843 | SH | SOLE | 1 | 74,843 | 0 | 0 | |
Achillion Pharmaceuticals Inc | COM | 00448Q201 | 18,908 | 2,424,136 | SH | SOLE | 1 | 2,424,136 | 0 | 0 | |
Agenus Inc | COM NEW | 00847G705 | 9,838 | 2,429,149 | SH | SOLE | 1 | 2,429,149 | 0 | 0 | |
Allscripts Healthcare Solutions Inc | COM | 01988P108 | 610 | 48,000 | SH | SOLE | 1 | 48,000 | 0 | 0 | |
Alnylam Pharmaceuticals Inc | COM | 02043Q107 | 46,198 | 832,549 | SH | SOLE | 1 | 832,549 | 0 | 0 | |
Atara Biotherapeutics Inc. | COM | 046513107 | 10,487 | 465,874 | SH | SOLE | 1 | 465,874 | 0 | 0 | |
Avexis Inc | COM | 05366U100 | 18,111 | 476,367 | SH | SOLE | 1 | 476,367 | 0 | 0 | |
Barclays Bank iPath Dow Jones-UBS Coffee Subindex TR ETN | ETN DJUBSCOFFE38 | 06739H297 | 3,194 | 144,200 | SH | SOLE | 1 | 144,200 | 0 | 0 | |
BioCryst Pharmaceuticals Inc | COM | 09058V103 | 6,353 | 2,237,066 | SH | SOLE | 1 | 2,237,066 | 0 | 0 | |
Biopharmx Corp | COM | 09072X101 | 455 | 700,636 | SH | SOLE | 1 | 700,636 | 0 | 0 | |
bluebird bio Inc | COM | 09609G100 | 26,495 | 612,025 | SH | SOLE | 1 | 612,025 | 0 | 0 | |
Bristol-Myers Squibb Co | COM | 110122108 | 15,424 | 209,701 | SH | SOLE | 1 | 209,701 | 0 | 0 | |
Celldex Therapeutics Inc | COM | 15117B103 | 5,550 | 1,264,227 | SH | SOLE | 1 | 1,264,227 | 0 | 0 | |
Corium International Inc | COM | 21887L107 | 2,960 | 852,961 | SH | SOLE | 1 | 852,961 | 0 | 0 | |
CytRx Corp | COM PAR $.001 | 232828509 | 1,040 | 466,200 | SH | SOLE | 1 | 466,200 | 0 | 0 | |
Dicerna Pharmaceuticals Inc | COM | 253031108 | 6,081 | 2,026,894 | SH | SOLE | 1 | 2,026,894 | 0 | 0 | |
Five Prime Therapeutics Inc | COM | 33830X104 | 1,848 | 44,701 | SH | SOLE | 1 | 44,701 | 0 | 0 | |
Global Blood Therapeutics Inc | COM | 37890U108 | 1,612 | 97,138 | SH | SOLE | 1 | 97,138 | 0 | 0 | |
Incyte Corp | COM | 45337C102 | 31,371 | 392,236 | SH | SOLE | 1 | 392,236 | 0 | 0 | |
Intercept Pharmaceuticals Inc | COM | 45845P108 | 5,636 | 39,500 | SH | SOLE | 1 | 39,500 | 0 | 0 | |
Invuity Inc | COM NEW | 46187J205 | 2,154 | 226,042 | SH | SOLE | 1 | 226,042 | 0 | 0 | |
iShares 20+ Year Treasury Bond ETF | 20 YR TR BD ETF | 464287432 | 6,251 | 45,000 | SH | SOLE | 1 | 45,000 | 0 | 0 | |
Kite Pharma Inc | COM | 49803L109 | 14,276 | 285,518 | SH | SOLE | 1 | 285,518 | 0 | 0 | |
La Jolla Pharmaceutical Co | COM PAR $.0001 2 | 503459604 | 18,818 | 1,176,146 | SH | SOLE | 1 | 1,176,146 | 0 | 0 | |
Masimo Corp | COM | 574795100 | 1,360 | 25,900 | SH | SOLE | 1 | 25,900 | 0 | 0 | |
Mirati Therapeutics Inc | COM | 60468T105 | 716 | 131,052 | SH | SOLE | 1 | 131,052 | 0 | 0 | |
MNKD 01/20/2017 PUT 3 | PUT | 56400P201 | 912 | 4,385 | SH | Put | SOLE | 1 | 4,385 | 0 | 0 |
Natera Inc | COM | 632307104 | 382 | 31,693 | SH | SOLE | 1 | 31,693 | 0 | 0 | |
Nivalis Therapeutics Inc | COM | 65481J109 | 138 | 30,000 | SH | SOLE | 1 | 30,000 | 0 | 0 | |
Omeros Corp | COM | 682143102 | 5,542 | 526,788 | SH | SOLE | 1 | 526,788 | 0 | 0 | |
Regenxbio Inc | COM | 75901B107 | 1,942 | 242,784 | SH | SOLE | 1 | 242,784 | 0 | 0 | |
Sensus Healthcare Inc | UNIT 99/99/9999 | 81728J208 | 1,006 | 155,000 | SH | SOLE | 1 | 155,000 | 0 | 0 | |
SPDR Gold Shares ETF | GOLD SHS | 78463V107 | 10,497 | 83,000 | SH | SOLE | 1 | 83,000 | 0 | 0 | |
Symmetry Surgical Inc | COM | 87159G100 | 12,109 | 922,215 | SH | SOLE | 1 | 922,215 | 0 | 0 | |
Viveve Medical Inc | COM | 92852W204 | 3,341 | 814,946 | SH | SOLE | 1 | 814,946 | 0 | 0 |